Preprint
Common genetic variants near SLC2A2 and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial
Abstract
Optimizing second-line therapy for type 2 diabetes is challenging due to interindividual variability in response. We conducted a pharmacogenomic genome-wide association study (GWAS) in the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin, when added to metformin in a diverse population. We …
Authors
Li JH; Szczerbinski L; Tripputi M; Liu H; Nam S; Mujica E; Emmanouilidou A; Wangden TY; Citko-Rojewska A; Konopka P
DOI
10.1101/2025.10.07.25336827
Preprint server
medRxiv